Introduction
[6,7] due primarily to a larger increase in lumen immediately after stenting as compared to PTCA. However, both Percutaneous transluminal angioplasty (PTCA) was first studies showed a larger amount of late lumen loss with introduced into the therapy of patients with coronary artery stents. There is increasing evidence that stents, while stenosis in the late seventies [1] . In the two decades since, preventing vascular constriction, induce at least the same this method has become standard therapy for patients amount of vascular smooth muscle cell (SMC) prolifersuffering from all forms of coronary artery disease. The ation as 'classical' PTCA because of additional circumsuccess rate of the procedure itself has increased from 61 ferential deep vessel wall injury [8] . As in the case of percent in the late seventies to well over 90 percent from stents additional treatment to limit late lumen loss can the mid-eighties onwards [2] . However, long-term success finally concentrate on inhibiting SMC proliferation and of PTCA remains limited by late restenosis caused by extracellular matrix formation pharmacological agents not vessel wall proliferation that occurs in 20 to 40 percent of limited by systemic side-effects have huge therapeutic all patients to such an extent that a second PTCA is potential. necessary [2] . As in the mid-90s about 500,000 primary PTCA procedures were carried out in the USA [3] and about 200,000 in Europe [4] , this accounts for more than 2. Mechanisms of restenosis 230,000 patients per year eligible for a second invasive procedure due to recurrent angina. A hypothetical reducThe precise molecular processes responsible for tion of the incidence of restenosis by 10-15 percent per pathological restenosis after PTCA with or without stent year would reduce annual treatment costs by almost 1.5 implantation in humans are still not well understood to billion dollars in the USA and Europe alone. Up to now a date. Several animal models to investigate mechanisms and large number of clinical trials performed to investigate pharmacological prevention of restenosis have been dewhether systemic administration of drugs which were veloped and extensively used, however, none of the effective in animal models of restenosis were efficacious in models has been able to accurately reflect the complexity men have failed. The reason for this discrepancy between of the processes underlying the human disease [9] . Neverpre-clinical and clinical studies could be that doses effectheless experiments in rats, rabbits and increasingly so in tive in experimental settings have not been applicable to pigs are the only way to test new pharmacological principatients due to other cardiovascular effects of these drugs ples for the prevention of restenosis before applying them [5] . If technical advances, such as the use of stents, will by clinically and, in addition to cell culture experiments in themselves be able to achieve the goal of a significant vitro, they provide at least limited insights into the reduction of restenosis rates long term still needs to be pathophysiology of restenosis. The different mechanisms studied. Two clinical trials with 6 months follow up have involved in restenosis as well as their relative importance been published, both showing a reduction in restenosis have recently been reviewed in this journal by Bauters and colleagues [10] . In our review we will therefore only briefly recapitulate the response to experimental injury and between the two receptors remained essentially unchanged then focus on the emerging role of endothelin-1 (ET) and [23] . Up to now no study has been published investigating ET receptor antagonists in restenosis.
ET receptor density and subtype distribution after PTCA in Immediately after injury of a coronary artery by PTCA men. However, several papers on experimental studies platelets accumulate at the site of injury and on activation have been published, characterising the most widely used by thrombin release a multitude of substances, including species in restenosis. In rats after PTCA of carotid arteries serotonin, platelet derived growth factor, and further a significant increase in mRNA levels of more then 20 promote thrombin release [11] . Medial SMCs shift from a times over controls was seen for ET receptors at both day A contractile to a synthetic phenotype, migrate, proliferate, 3 and day 7 after injury [24] . Stimulation of mRNA levels and produce extracellular matrix. Taken together these for ET receptors was also significantly elevated, albeit B responses lead to neointimal hyperplasia [12] and constiless pronouncedly so (10-15 fold over controls). In tute, at least in experimental models, a major component of contrast, in rabbit carotid artery investigated autoradiorestenosis.
graphically four weeks after endothelial denudation it was found that ET receptors were predominately located in A the media, while ET receptors were localised mainly in B 3. Endothelin in restenosis the neointima [25] . This finding appears to be species specific and valid for rabbits only. Therefore the predictive Endothelin, a 21 amino acid peptide, has been described value of this species for the evaluation of ET receptor as the most potent endogenous vasoconstrictor known [13] .
antagonists in restenosis with regard to compounds of As excellently reviewed by Rubanyi and Polokoff [14] , ET different subtype selectivity may be limited. A recent study binds in an autocrine / paracrine fashion to two different in our laboratory has investigated ET receptor density and specific high affinity receptors, named ET and ET . distribution 4 weeks after PTCA in pig coronary arteries. cerning the receptor ratio. Over the last few years a considerable effort has been
We have tried to schematically visualise the role of ET made by several groups to better define the role of ET and in all processes involved in restenosis after PTCA in Increased tissue ET immunoreactivity has been shown in ing the proposed mechanisms will be discussed; however, human atherosclerotic plaques [15, 16] . This is in accordthe role of ET in monocyte adhesion and SMC phenotype ance with the finding that immediately after PTCA plasma changes still warrants further investigations. The effect of ET levels were elevated in the coronary sinus of patients elevated ET levels on vascular SMC hypertrophy and [17] and even more so in the dilated coronary artery distal hyperplasia has been studied both in vitro and in vivo by to the site of PTCA [18] . However, these elevated levels injecting exogenous ET. In SMCs cultured from human 211 27 need not necessarily originate from the atherosclerotic vascular smooth muscle ET from 10 to 10 M induced plaque alone. It has been shown in cell culture experiments concentration dependent mitogenesis and proliferation; this that SMCs themselves are able to produce and secrete was mediated via ET receptors and correlated closely A endothelin [19] . In rat carotid arteries mRNA levels for with receptor density [28] . In cultured rat aortic SMCs ET 211 27 endothelin converting enzyme (ECE, [20] ) as well as ECE from 10 to 10 M also induced concentration depenactivity itself were increased after balloon injury [21] . dent mitogenic effects [29] . This ET-induced mitogenesis Application of the rather unspecific neutral endopeptidase could be inhanced significantly by adding angiotensin II in inhibitor phosphoramidon, which also blocks ECE activity the same concentration range [29] . It has been suggested and therefore should reduce ET levels, was able to reduce that ET exerts its direct mitogenic activity mainly through neointima proliferation in rats after balloon injury of the protein kinase C activation [30] . In isolated porcine carotid artery [21] .
coronary SMCs ET concentration dependently stimulated 28 While both ET and ET receptors have been shown to the synthesis of collagen type I with a maximum at 10
A B be present in human coronary arteries the overwhelming M ET [31] . This effect was shown to be mediated via ET A majority of receptors located on SMC are of the ET receptors [31] , as addition of the ET receptor antagonist A A subtype [22] . Despite up-regulation in ET receptor density BQ 123 (10 mM) almost totally blocked ET induced in human atherosclerotic coronary arteries the relation extracellular matrix production. In vivo, in the rat model of importantly still, chronic infusion of Ang II over two weeks resulted not only in elevated blood pressure, but also in a significant increase of media thickness of basilar and small mesenteric arteries in rats [36] as well as elevated arterial tissue ET levels. As application of the selective ET receptor antagonist LU 135252 was able to A totally inhibit the vascular hypertrophy but only partially the concomitant blood pressure increase, part of the structural effect of the two co-mitogens seem to be pressure independent [36] . Thrombin, one of the substances activated at the site of injury and promoting platelet aggregation as well as acting as a growth promoter, has also been shown to stimulate endothelin secretion [37] . Consequently the thrombin inhibitor hirudin was able to inhibit thrombin induced ET release [38] . It has been suggested that in a canine model of coronary artery endothelial injury and constriction the extend of platelet accumulation was positively correlated to the severity of neointimal proliferation [39] . antagonism by BQ 788, was able to reduce cyclic coronary flow reductions by 50% compared to controls [40] . Although outside the scope of that acute study this might indicate an additional beneficial impact on restenosis by reduction of local thrombin formation early after PTCA. neointima formation after balloon-induced endothelial antagonists was endothelial denudation by a balloon denudation of carotid arteries, infusion of ET (5-500 catheter in rat carotid arteries. All studies done in this pmol / kg) for 30 min intraarterially induced a dose depenmodel [41] [42] [43] [44] [45] [46] have one specific methodological detail in dent and significant increase of intimal hyperplasia decommon: The rats were treated from 3 days prior to 14-21 termined 14 days later [32] . Continuous intravenous infudays after balloon injury. One of the first substances to be sion (5 pmol / kg / min) for a 2 week period [33] increased tested was the peptidic, selective ET receptor antagonist A intimal hyperplasia significantly compared to injured con-BQ 123 [41] . The drug was applied once daily intraperitotrols without additional ET infusion.
neally with either 0.8 or 8 mg / kg and showed no effect on There is increasing evidence that ET in restenosis and in neointima proliferation [41] . This is perhaps not surprising, other forms of vascular diseases is associated with arterial as BQ 123 has a very short half life, intraperitoneally hypertrophy (e.g. hypertension, atherosclerosis) and acts as applied substance is almost immediately absorbed, and a co-mitogen in concert with other growth factors [34] thus one might assume that no or only very little substance leading to hyperplasia. An ET receptor mediated interwas present at the site of injury for the by far greater part A action between ET and vascular endothelial cell growth of the experimental time. Two further peptidic compounds factor to modulate proliferation, and possibly neovasculariwere applied in the rat model, the mixed ET receptor [45] , both of them given subcutahas been shown to act as a co-mitogen to ET in vitro [29] , neously. In contrast to the results discussed above, both the providing evidence for common intracellular signalling selective ET receptor antagonist FR 139317 and the A pathways. In addition Ang II, as ET, potently stimulates mixed ET receptor antagonist TAK 044 were able to A / B extracellular matrix synthesis in cell culture [31] . More reduce neointima proliferation by 76% [45] and 80% [44] 209670, also applied intraperitoneally, was shown to setting was carried out so far. In our laboratory a study in reduce the neointima / media ratio by 52% [42] . Up to now land race pigs applying PTCA in the LAD according to two studies in rats have been published in which a standard clinical protocols was done [27] . 5 minutes prior selective ET receptor antagonist was applied orally. The to balloon inflation 3 mg / kg of the ET receptor antago-A A compound BMS 182874, tested with a daily oral dose of nist LU 135252 was administered intravenously and after 100 mg / kg, was able to reduce neointima / media ratio by recovery from anaesthesia the animals received LU 135252 35% [43] . In our laboratory we evaluated the dose at a dose of 30 mg / kg / day orally for 4 weeks. At the end response of the ET receptor antagonist LU 135252 from of the experiments the LAD was excised and frozen to A 20 to 100 mg / kg / day orally and found a reduction of allow not only histological examination, but also ET neointima / media ratio of 14 to 25% [46] . In a somewhat receptor autoradiography and receptor distribution studies. different approach the immediate restenotic response after Treatment with the ET receptor antagonist normalised A endothelial injury to rat thoracic aorta was investigated by both ET as well as ET receptor numbers and led to a A B measuring incorporation of radiolabeled thymidine [47] . In 45% reduction in neointima / media ratio [27] . In a second this study, which was terminated 3 days after injury, the series of experiments we investigated the effect of 30 selective ET receptor antagonist BMS 182874 reduced mg / kg / day orally of the ET receptor antagonist LU receptor antagonist bosentan a 35% reduction was stent post PTCA of the LAD, again without pretreatment achieved [47] . However, as both substances were only of the animals. A similar reduction in the proliferative used in one and the same dose, no differences in the response of 35% was seen 4 weeks after this procedure efficacy of those two antagonists should be deduced. (Fig. 2 , unpublished results from our laboratory). The In the Yucatan micropig [48] PTCA in an iliac artery as selective ET receptor antagonist A 127722 was also A well as in a carotid artery was carried out 3 days after oral tested in pigs with coronary artery stents [49] . After 28 pre-treatment with the ET receptor antagonist A 127722.5 days of oral treatment (b.i.d.) a maximal reduction in A (7.5 mg / kg, twice daily). Four weeks after PTCA the two neointima formation of about 30%, which compares to the arteries were excised and morphological changes were one seen by us (Fig. 2) , has been reported [49] . Further assessed. As compared to placebo, both medial area and experiments to determine dose-response relationships of neointima / media ratio were significantly reduced by treatdifferent ET receptor antagonists in coronary restenosis ment with this selective ET receptor antagonist. In after PTCA or stenting are currently under investigation.
A addition, collagen disposition was significantly reduced From the results described above it can be concluded [48] , thus confirming results predicted from in vitro studies that both in rat and in pig experiments blockade of the ET A of ET receptor antagonism and collagen synthesis [31] .
receptor is responsible for reduction of restenosis. This A However, antiproliferative effects in the carotid artery were conclusion is also valid in the light of the effects discussed markedly less pronounced than in the iliac artery [48] indicates an important role of endothelin as a (co-)mitogen 
